Molecular Insights Consulting was established in 2024 by Dr. Felix Vajdos, who brings over two decades of experience in early-stage drug discovery at Pfizer Inc. where he contributed to 8 clinical candidates, including 3 marketed drugs. Dr. Vajdos provides experienced scientific leadership without adding full-time headcount—whether that means tackling difficult hit identification and mechanism-of-action questions, strengthening hit validation and lead optimization, guiding external CRO work, or helping teams evaluate new technologies and approaches. Molecular Insights Consulting works as an embedded partner to project teams—collaborating closely with medicinal chemists, biologists, biochemists, and computational chemists to move programs forward with clear, actionable insight to effectively convert raw screening hits into high-confidence leads.
Dr. Vajdos's mission is to assist clients in finding and developing top-quality chemical matter essential for their drug discovery programs. By leveraging decades of experience in biophysics and enzymology, Molecular Insights Consulting is well-equipped to support your lead optimization strategies throughout the project's lifecycle.

Hit ID begins with a clear, focused screening strategy that is appropriate for the target, integrating insights from biophysics and enzymology to enhance the effectiveness of drug discovery consulting. Our approach includes a robust screening strategy and development process, CRO management, meticulous data analysis, and thorough druggability assessment, all designed to optimize lead optimization strategies.

We help clients prioritize screening hits to ensure that chemistry efforts are concentrated on those with the highest likelihood of becoming leads, which is essential in drug discovery consulting. Our expertise spans biophysics and enzymology, focusing on critical areas such as biophysical characterization, solubility assessment, target-ligand engagement, and mechanism of action, all of which are vital for implementing effective lead optimization strategies.

Once leads have been identified, we utilize lead optimization strategies through advanced structural and biophysical methods. Our expertise in biophysics and enzymology enhances our drug discovery consulting, employing techniques such as Structure-Based Drug Design (X-ray, Cryo-EM) and Biophysical Analysis (SPR, ITC, TSA, BLI, Mass Photometry).

In addition to consulting services, we are an independent representative for Biosensing Instruments (Flagstaff, AZ, USA), specializing in SPR microscopy.